Acumen Pharmaceuticals (ABOS) to Release Quarterly Earnings on Thursday

Acumen Pharmaceuticals (NASDAQ:ABOS) will likely be issuing its quarterly earnings data before the market opens on Thursday, March 27th. Analysts expect the company to announce earnings of ($0.47) per share for the quarter. Parties that wish to register for the company’s conference call can do so using this link.

Acumen Pharmaceuticals Stock Performance

NASDAQ:ABOS opened at $1.24 on Tuesday. The company has a market cap of $74.50 million, a price-to-earnings ratio of -0.90 and a beta of 0.02. Acumen Pharmaceuticals has a 1 year low of $1.10 and a 1 year high of $4.39. The stock’s 50 day simple moving average is $1.41 and its two-hundred day simple moving average is $2.02. The company has a debt-to-equity ratio of 0.14, a current ratio of 10.43 and a quick ratio of 10.43.

Insider Buying and Selling

In related news, CFO Matt Zuga sold 28,902 shares of the stock in a transaction on Thursday, January 23rd. The stock was sold at an average price of $1.72, for a total transaction of $49,711.44. Following the sale, the chief financial officer now owns 231,744 shares in the company, valued at approximately $398,599.68. This represents a 11.09 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CEO Daniel Joseph Oconnell sold 47,778 shares of Acumen Pharmaceuticals stock in a transaction on Friday, January 3rd. The stock was sold at an average price of $1.84, for a total transaction of $87,911.52. Following the transaction, the chief executive officer now directly owns 454,707 shares of the company’s stock, valued at $836,660.88. The trade was a 9.51 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 131,526 shares of company stock worth $233,124. Insiders own 7.10% of the company’s stock.

About Acumen Pharmaceuticals

Acumen Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer’s disease. The company focuses on advancing a targeted immunotherapy drug candidate sabirnetug (ACU193), a recombinant humanized immunoglobulin gamma 2 that completed Phase I clinical trial to target soluble amyloid-beta oligomers.